Filing Signals

Source: SEC EDGAR Compiled 2026-09-14 08:28 UTC All 21 checks passing

← All events

Elicio Therapeutics, Inc.

CIK 1601485 ELTX·Pharmaceutical Preparations · All EDGAR filings ↗

Progression

  1. Material weakness 10-K
  2. Going concern 10-K/A +48d
Refine

Going concern Filing comparison

Elicio Therapeutics, Inc.'s going-concern disclosure changed

Substantial doubt about ability to continue as a going concern → Risk-factor language only

These forward-looking statements include, but are not limited to, statements about: •our financial condition, including our ability to obtain the funding necessary to advance the development of ELI-002 7P and any other current or future product candidates, our ability to continue as a going concern and our cash runway; •the ability of our clinical trials to demonstrate safety and efficacy of our product candidates, and other positive results; •our ability to utilize our platform to develop a pipeline of product candidates to address unmet needs in oncology and other disease areas; •the…
Evidence
Blank check
No
Comparable
Yes
Current state
risk_factor_only
Current state label
Risk-factor language only
Direction
eased
Located in
risk factors / forward-looking statements only
Prior filed
2026-03-12
Prior form
10-K
Prior state
substantial_doubt
Prior state label
Substantial doubt about ability to continue as a going concern
Source
ASC 205-40 going-concern note comparison
Why
Disclosure about the company's ability to continue as a going concern changed compared with its previous report.

Source filing ↗ Prior filing ↗

Material weakness Filing comparison

Elicio Therapeutics, Inc. reported internal control effective again after a material weakness

Material weakness in internal control → Internal control reported effective

The weakness was first reported on 2025-03-31 — 346 days and 1 annual report before this one.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) in Internal Control-Integrated Framework (2013). Based on our assessment, management concluded our internal control over financial reporting was effective as of December 31, 2025, based on the COSO criteria. Inherent Limitation on the Effectiveness Over…
Evidence
Current state
effective
Current state label
Internal control reported effective
Direction
remediated
Prior filed
2025-03-31
Prior form
10-K
Prior state
material_weakness
Prior state label
Material weakness in internal control
Remediation stated
Yes
Severity
normal
Source
Item 9A internal control conclusion, compared with the prior filing
Weakness annual reports
1
Weakness days reported
346
Weakness first reported
2025-03-31
Why
The company's conclusion on internal control over financial reporting changed: a material weakness was newly reported, or a previously reported one no longer appears.

Source filing ↗ Prior filing ↗